undamentalytics Newsletter

Verguet Patrick B: insider trades

Officer at Edwards Lifesciences. No open-market purchases and 44 sales not made under a pre-set plan, reported from February 18, 2010 to May 31, 2017.

What happened after Verguet Patrick B’s sales?

After their sales, the shares moved +2.9% against the index over 12 months on average (a negative figure means selling was the right call); 48% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Verguet Patrick B: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 44 +1.2% +2.9% 46% 8 −0.38 0.71 No reliable evidence
Sales, 12 months after the report 44 +2.9% +3.5% 48% 8 0.07 0.95 No reliable evidence
Sales, 12 months after the trade 44 +3.7% +2.9% 48% 8 0.13 0.90 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Edwards Lifesciences EW CVP, Europe044February 18, 2010May 31, 2017

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
May 31, 2017May 31, 2017 EW Sale $1,148,800 −5.6%+6.3%+5.0%
May 19, 2017May 17, 2017 EW Sale $2,560,776 −1.8%+3.8%+3.9%
May 15, 2017May 12, 2017 EW Sale $1,283,845 −2.1%+4.5%+8.4%
August 29, 2016August 26, 2016 EW Sale $574,400 −29.1%−17.4%−16.7%
August 24, 2016August 23, 2016 EW Sale $1,770,229 −26.2%−17.2%−17.8%
August 9, 2016August 5, 2016 EW Sale $1,134,800 −18.7%−14.2%−13.0%
August 1, 2016July 28, 2016 EW Sale $1,148,650 −15.3%−16.5%−14.0%
May 18, 2016May 16, 2016 EW Sale $1,335,710 +9.8%−3.7%−9.2%
May 4, 2016May 2, 2016 EW Sale $748,020 +2.1%−13.4%−14.1%
February 22, 2016February 18, 2016 EW Sale $435,000 +7.9%−19.3%−20.5%
February 8, 2016February 4, 2016 EW Sale $670,000 +26.6%−7.3%−14.1%
December 1, 2015November 27, 2015 EW Sale $1,233,750 +10.6%−7.5%−5.4%
November 4, 2015November 2, 2015 EW Sale $687,463 +8.3%+11.6%+14.4%
August 3, 2015July 31, 2015 EW Sale $770,000 +4.5%+46.3%+44.9%
June 1, 2015May 29, 2015 EW Sale $1,267,461 +13.4%+50.5%+51.4%
March 2, 2015February 26, 2015 EW Sale $1,347,500 −3.0%+35.0%+36.2%
February 23, 2015February 19, 2015 EW Sale $672,500 −4.0%+37.9%+35.6%
November 12, 2014November 10, 2014 EW Sale $618,500 +3.3%+21.9%+22.2%
November 3, 2014October 30, 2014 EW Sale $1,201,500 +9.5%+23.9%+24.3%
October 29, 2014October 27, 2014 EW Sale $1,760,000 +2.5%+24.3%+21.6%
August 14, 2014August 13, 2014 EW Sale $744,900 +24.1%+40.2%+41.4%
August 12, 2014August 8, 2014 EW Sale $472,950 +24.9%+41.4%+41.5%
August 6, 2014August 4, 2014 EW Sale $1,410,800 +21.9%+41.5%+49.8%
August 1, 2014August 1, 2014 EW Sale $460,000 +25.0%+49.8%+53.2%
May 7, 2014May 5, 2014 EW Sale $830,400 +10.2%+35.7%+34.6%
August 13, 2013August 1, 2013 EW Sale $1,463,000 −17.9%+13.2%+10.3%
March 1, 2013February 28, 2013 EW Sale $172,440 −31.5%−43.9%−44.2%
November 6, 2012November 2, 2012 EW Sale $711,440 −11.5%−56.5%−55.6%
October 29, 2012October 24, 2012 EW Sale $2,222,191 −0.2%−52.0%−42.8%
August 31, 2012August 29, 2012 EW Sale $1,020,000 −14.0%−51.8%−49.5%
July 30, 2012July 26, 2012 EW Sale $2,536,675 −17.4%−55.2%−57.8%
June 4, 2012May 31, 2012 EW Sale $426,500 +9.8%−53.4%−50.6%
May 23, 2012May 21, 2012 EW Sale $419,250 +7.0%−53.9%−50.0%
November 1, 2011October 28, 2011 EW Sale $608,320 −13.0%+3.4%+1.9%
August 30, 2011August 26, 2011 EW Sale $1,238,810 −15.3%+17.8%+13.7%
May 23, 2011May 20, 2011 EW Sale $889,300 −8.3%−5.6%−5.7%
May 12, 2011May 10, 2011 EW Sale $1,061,160 −10.2%−6.9%−5.6%
February 8, 2011February 4, 2011 EW Sale $1,044,280 −2.1%−21.2%−20.3%
November 24, 2010November 24, 2010 EW Sale $1,318,000 +16.3%−5.1%−3.7%
November 19, 2010November 17, 2010 EW Sale $1,310,000 +17.6%−5.8%−6.6%
November 8, 2010November 4, 2010 EW Sale $1,294,600 +23.1%+7.5%+12.0%
July 27, 2010July 23, 2010 EW Sale $576,700 +3.7%+3.6%+9.5%
February 26, 2010February 24, 2010 EW Sale $408,825 +9.8%+60.3%+66.6%
February 18, 2010February 16, 2010 EW Sale $395,100 +9.1%+73.9%+77.9%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Verguet Patrick B traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.